Shire, which sells some of the world's most expensive prescription drugs, believes the U.S. market will continue to recognise the value of its rare disease treatments, despite sabre-rattling on pricing by President-elect Donald Trump. "I think we are in good position to prove the value of our products but, of course, there will be challenges," Chief Executive Flemming Ornskov said on Tuesday on the sidelines of the World Economic Forum in Davos.
- MarketWatch•5 days ago
U.K. stocks gained for a 14th straight day on Friday, extending their record winning run as a soft pound helped spur investors to buy into British multinationals.
- American City Business Journals•6 days ago
A new class action lawsuit accuses Shire plc’s U.S. subsidiary in Lexington of monopolizing the market for its ADHD drug Intuniv by conspiring with Actavis to delay the commercial release of a cheaper generic version. New Jersey-based Actavis (NYSE:ACT) won FDA approval to launch a cheaper, generic version of Intuniv in October 2012. Shire was effectively paying Actavis “tens of millions of dollars” to maintain a monopoly, the suit claimed.
S7E.DU: Summary for SHIRE PLC LS-,05 - Yahoo Finance
SHIRE PLC LS-,05 (S7E.DU)
Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
As of 10:30AM CET. Market open.
|Day's range||55.36 - 55.36|
|52-week range||50.84 - 56.21|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|